TELESTA THERAPEUTICS INC T.TST

AGM filled w details plus potential minor sht-term catalysts

[rgonlyfactspls]

Few tidbits in no particular order: - BLA fee waiver (all or majority of fee) applied to via two other sources. Expect an answer prior to BLA filing. -Third party commercial assessment of market and pricing s/b known by end of Nov/early Dec. Important to maximize partnering discussions. - Current estimate for cost per MCNA dose $3,000 and number of doses 15 to 24. Also mentioned "very high profit margin". - Assessment of Montreal production facility (for MCNA) also underway (and needed for FDA). Goal is also to be in production if/when BLA approved. No major deficiencies expected. - Meeting with two PR-type firms following AGM (i.e., this aft). Comprehensive campaign to raise awareness across the spectrum of parties of interest (investment bankers --> Joe/Mary investor). - Expect 2-3 new analyst reports out by end of this 2014 (if I heard timing correctly). - Telesta approved. Graphic look great. Transition s/b noticeable asap (possibly starting in a week). Expect launch of new website. - Mr. Gubitz did not receive necessary votes to be elected/continue as a Director. - Target partner in U.S. appears more likely a mid size pharma/ biotech with experience, sales force and capital; albeit also discussed option of building proprietary sales force for U.S. And, a positive quote from Dr. Berendt to end this brief summary..."We think we are well positioned to go forward with FDA". Of course he also mentioned several times that approval is not guaranteed. Hopefully others will add/ confirm/ correct. And, PPT slides shown at AGM posted sooner-than-later. rg

[majimoto]

Thanks, rg. Much appreciated.

[cheetio]

Mr. Gubitz did not receive necessary votes to be elected/continue as a Director....amen....but then its an easy way out..might have been his game plan..

[beechguy]

Sometimes message boards can be very effective:) Good riddance GG and your "well timed" share dumping... Although he did help get rid of Graeme, and for that I will be forever indebted. beech

[IWillRetireSoon]

Wow this is exciting: " Current estimate for cost per MCNA dose $3,000 and number of doses 15 to 24. Also mentioned "very high profit margin"" Easy math 20 doses times $3000 = $60,000 per patient.   Did someone say there are 10,000 cases?    Even if only half are eligible for the treatment, I get a number of $300 million. Yet this is only the US numbers.  

[conspiTheory]

[...] More than 12 million new cases of bladder cancer occur annually worldwide, making it the seventh most common cancer for men and seventeenth for women, according to a review paper in 2009 in the World Journal of Urology. The disease is three to four times more common in developed countries and 90 percent of cancers are diagnosed past the age of 55. [...] https://www.reuters.com/article/2014

[rgonlyfactspls]

CT re 12,000,000 new bladder cancer cases worldwide each year....Dr. Berendt spoke to the cost of treatment for bladder cancer is approx $230k per patient (I assume this is a U.S. cost). Based on 2010 figures which he then emphasised would likely be higher today. In answering a question if there might be any concern having U.S. health insurance covering the cost of MCNA?...he did not indicate

[DamnYankees]

RGfcatspls, I commend you. You seem to be one of the few insightful people here. Between people posting unrelated information to those misleading readers,for example with suggestions that no pharma will partner until after an FDA approval (are they a new investor to biotech or a misleader), this is not a very informative or factual source of information.One question I had was whether the company

[rgonlyfactspls]

DamnYankees...re your question... "whether the company will disclose the results of the 3rd party market analysis for the MCNA treatment to shareholders?"...Unfortunately, your question was not asked during formal meeting (that I caught) and not part of presentation. However, possibly someone may have asked after presentation during informal, social session. If someone did that is on

[DamnYankees]

I hope that you can understand the essence of my question. Most investors do some form of research before buying a stock. But if you were researching Bioniche you would be very confused by the company's own communication. The trial results are self explanatory and very compelling but what the heck is the market size for the drug?The potential market is somewhere between less than 10,000

[18tee20]

DamnYankees, you should re-read rgonlyfafctspls post about off label usage. Bioniche is not allowed to speculate on these numbers, so they are locked in with the MCNA target population for high-grade non-muscle invasive bladder cancer patients who have failed BCG therapy, i.e. BCG-refractory or BCG-relapsing, at less than 10,000 patients per year U.S..... I don't think market analysts will

[DamnYankees]

If your's and Rgfacts logic is correct than you could perhaps make the case that an Orphan Drug submission was filed with the intented consequence being rejection. If you wanted to demonstrate to a partner or partners early in negotiations that the FDA itself believed that the market for MCNA was much much bigger than the sub 10K segment,as  targeted and defined in the first phase 3 trial

[conspiTheory]

so IF FDA approve it, the label for MCNA will be as much as important. Thank you for the AGM info.